DMTR.L Regulatory News (DMTR)

15 September 2015

OXACO plc

("OXACO" or the "Company")

Appointment of directors

OXACO is pleased to confirm the appointment of Mark Warne as an additional non - executive director and Professor Lee Cronin as Founding Scientific Director, with immediate effect.

Mark Warne, aged 40, is currently Head of Healthcare at IP Group plc. Mark has been with IP Group plc since 2008 developing and commercialising healthcare technology innovations primarily from research intensive universities. Mark currently represents IP Group plc on the boards of a number of its life science portfolio companies. He joined IP Group plc from pre-clinical drug discovery contract research organisation, Exelgen, where he was managing director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.

Following completion of the acquisition of Cronin 3D limited, Mark Warne owns 96,742 ordinary shares in the Company, representing approximately 0.07% of the enlarged issued share capital of the Company.

Professor Cronin, aged 42, is the Regius Chair of Chemistry in the Department Chemistry at the University. He was elected to the Fellowship of the Royal Society of Edinburgh, the Royal Society of Chemistry, and appointed to the Gardiner Chair in April 2009. He was awarded a Philip Leverhulme Prize by the Leverhulme Trust in 2007. He was awarded the Corday-Morgan medal of the Royal Society of Chemistry in 2012. Professor Cronin has a large active group at the University of Glasgow performing cutting-edge research into how complex chemical systems, created from non-biological building blocks, can have real-world applications with wide impact. Professor Cronin has published in excess of 300 peer-reviewed articles in a number of journals and has given over 280 invited presentations at conferences and universities worldwide.

Following completion of the acquisition of Cronin 3D Limited, Professor Cronin owns a beneficial interest in 54,175,520 ordinary shares in the Company, representing approximately 10.3% of the enlarged issued share capital.

The Company confirms there are no additional matters that require to be disclosed in accordance with paragraph (g) Schedule Two AIM Rules for Companies.